140 related articles for article (PubMed ID: 22737998)
1. Short-term impact of intravitreal ranibizumab injection on axial ocular dimension and intraocular pressure.
Goktas A; Goktas S; Atas M; Demircan S; Yurtsever Y
Cutan Ocul Toxicol; 2013 Mar; 32(1):23-6. PubMed ID: 22737998
[TBL] [Abstract][Full Text] [Related]
2. Monitoring intraocular pressure changes after intravitreal Ranibizumab injection using rebound tonometry.
Fuest M; Kotliar K; Walter P; Plange N
Ophthalmic Physiol Opt; 2014 Jul; 34(4):438-44. PubMed ID: 24731161
[TBL] [Abstract][Full Text] [Related]
3. Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure.
Gismondi M; Salati C; Salvetat ML; Zeppieri M; Brusini P
J Glaucoma; 2009 Dec; 18(9):658-61. PubMed ID: 20010243
[TBL] [Abstract][Full Text] [Related]
4. The ocular pulse amplitude at different intraocular pressure: a prospective study.
Knecht PB; Bosch MM; Michels S; Mannhardt S; Schmid U; Bosch MA; Menke MN
Acta Ophthalmol; 2011 Aug; 89(5):e466-71. PubMed ID: 21401909
[TBL] [Abstract][Full Text] [Related]
5. Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab.
Theoulakis PE; Lepidas J; Petropoulos IK; Livieratou A; Brinkmann CK; Katsimpris JM
Klin Monbl Augenheilkd; 2010 Apr; 227(4):280-4. PubMed ID: 20408074
[TBL] [Abstract][Full Text] [Related]
6. The Effects of Intravitreal Ranibizumab, Aflibercept or Dexamethasone Implant Injections on Intraocular Pressure Changes.
Karakurt Y; Ucak T; Taslı G; Agcayazı B; İcel E; Yılmaz H
Med Sci Monit; 2018 Dec; 24():9019-9025. PubMed ID: 30542050
[TBL] [Abstract][Full Text] [Related]
7. Short-term effects of intravitreal bevacizumab on cornea and anterior chamber.
Güler M; Capkın M; Simşek A; Bilak S; Bilgin B; Hakim Reyhan A; Fırat M
Curr Eye Res; 2014 Oct; 39(10):989-93. PubMed ID: 24588314
[TBL] [Abstract][Full Text] [Related]
8. Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab.
Martinez-de-la-Casa JM; Ruiz-Calvo A; Saenz-Frances F; Reche-Frutos J; Calvo-Gonzalez C; Donate-Lopez J; Garcia-Feijoo J
Invest Ophthalmol Vis Sci; 2012 Sep; 53(10):6214-8. PubMed ID: 22915037
[TBL] [Abstract][Full Text] [Related]
9. Diurnal variation of axial length, intraocular pressure, and anterior eye biometrics.
Read SA; Collins MJ; Iskander DR
Invest Ophthalmol Vis Sci; 2008 Jul; 49(7):2911-8. PubMed ID: 18362106
[TBL] [Abstract][Full Text] [Related]
10. [Age-related macular degeneration and glaucoma: intraocular pressure monitoring after intravitreal injections].
Avetisov SE; Erichev VP; Budzinskaia MV; Karpilova MA; Gurova IV; Shchegoleva IV; Chikun EA
Vestn Oftalmol; 2012; 128(6):3-5. PubMed ID: 23367753
[TBL] [Abstract][Full Text] [Related]
11. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections.
Adelman RA; Zheng Q; Mayer HR
J Ocul Pharmacol Ther; 2010 Feb; 26(1):105-10. PubMed ID: 20187807
[TBL] [Abstract][Full Text] [Related]
12. Effect of prophylactic intraocular pressure-lowering medication (brinzolamide) on intraocular pressure after ranibizumab intravitreal injection: A case-control study.
Song S; Yu XB; Dai H
Indian J Ophthalmol; 2016 Oct; 64(10):762-766. PubMed ID: 27905340
[TBL] [Abstract][Full Text] [Related]
13. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Rosenfeld PJ; Heier JS; Hantsbarger G; Shams N
Ophthalmology; 2006 Apr; 113(4):623.e1. PubMed ID: 16581423
[TBL] [Abstract][Full Text] [Related]
14. [Intraocular pressure and ocular blood flow features intravitreal infection of anti-vascular endothelial growth factor agents].
Mamikonian VR; Galoian NS; Budzinskaia MV; Kazarian ÉÉ; Sdobnikova SV; Shmeleva-Demir OA; Rafaeian AA; Ryzhkova EG
Vestn Oftalmol; 2014; 130(5):16-21. PubMed ID: 25711057
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal injection of bevacizumab: changes in intraocular pressure related to ocular axial length.
Cacciamani A; Oddone F; Parravano M; Scarinci F; Di Nicola M; Lofoco G
Jpn J Ophthalmol; 2013 Jan; 57(1):63-7. PubMed ID: 23093311
[TBL] [Abstract][Full Text] [Related]
16. The effect of intravitreal triamcinolone on intraocular pressure.
Kramar M; Vu L; Whitson JT; He YG
Curr Med Res Opin; 2007 Jun; 23(6):1253-8. PubMed ID: 17559723
[TBL] [Abstract][Full Text] [Related]
17. Influence of axial length and postinjection reflux on sustained intraocular pressure elevation as a result of intravitreal anti-vascular endothelial growth factor therapy.
Hoang QV; Jung JJ; Mrejen S; Freund KB
Retina; 2014 Mar; 34(3):519-24. PubMed ID: 24240557
[TBL] [Abstract][Full Text] [Related]
18. Effects of change in intraocular pressure on axial eye length and lens position.
Leydolt C; Findl O; Drexler W
Eye (Lond); 2008 May; 22(5):657-61. PubMed ID: 17237751
[TBL] [Abstract][Full Text] [Related]
19. Impact of injection techniques on intraocular pressure (IOP) increase after intravitreal ranibizumab application.
Höhn F; Mirshahi A
Graefes Arch Clin Exp Ophthalmol; 2010 Oct; 248(10):1371-5. PubMed ID: 20407785
[TBL] [Abstract][Full Text] [Related]
20. Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide.
Benz MS; Albini TA; Holz ER; Lakhanpal RR; Westfall AC; Iyer MN; Carvounis PE
Ophthalmology; 2006 Jul; 113(7):1174-8. PubMed ID: 16647122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
